Electronic Pill Bottle Monitoring to Promote Medication Adherence for
Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 5 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Electronic Pill Bottle
What it measured
Main measures
Rate of perfect adherence
90-days post-enrollment
Quality of life (reported by participants)
Other measures (1)
Participant satisfaction
90-days post-enrollment
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Ability to provide individual written consent * Ability to understand sufficient levels of English to use the Pillsy app * Ability to come to Massachusetts General Hospital for two study visits over a 90-day window OR ability to access Zoom for virtual study visits * Possess a smartphone * Willingness to follow the study protocol
Exclusion criteria
* Presence of an MS relapse requiring acute management and/or hospitalization * Daily medication provided by allied health care workers * Foreign travel preventing electronic remote monitoring * Expectation of discontinuation of the oral disease modifying therapy (DMT) in the upcoming 90 days for any reason
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
People with multiple sclerosis (MS) have variable adherence to MS medications, making the full efficacy of disease modifying therapies unrealized and the assessment of true treatment failures challenging. Whereas some patients forget to take medications due to active lifestyles, others may have cognitive impairments that prevent them from organizing and planning their regular dosing schedules. An electronic pill cap ("Pillsy") has been developed to record pill taking, timing, and set reminders through a mobile app. Data on adherence can be captured and analyzed remotely for health care provider review.
Papers
Background
Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40. doi: 10.18553/jmcp.2013.19.s1.S24.Background
Schreiber K, Kant M, Pfleger C, Jensen HB, Oesterberg O, Hald AR, Nielsen FK, Rubak S. High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study. Patient Prefer Adherence. 2018 Jun 29;12:1139-1150. doi: 10.2147/PPA.S166278. eCollectionBackground
Erbay O, Usta Yesilbalkan O, Yuceyar N. Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis. J Neurosci Nurs. 2018 Oct;50(5):291-297. doi: 10.1097/JNN.0000000000000395.
Loading reviews and guidelines…
History
Started
Nov 2019
Main results due
Jan 2021
Finished
Jan 2021